Related Experiment Video

Updated: Jan 14, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.6K

Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing

Aubrey Martin1, Neda Shokrian2, Kristen J Kelley1

  • 1Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

The Journal of Investigative Dermatology
|October 16, 2025
PubMed
Abstract

Insights

Delgocitinib cream improved the molecular profile of frontal fibrosing alopecia (FFA) lesions. This topical treatment shows potential for FFA, with good tolerability and exploratory efficacy noted.

Area of Science:

  • Dermatology
  • Immunology
  • Molecular Biology

Background:

  • Frontal fibrosing alopecia (FFA) is a progressive scarring alopecia with limited treatment options.
  • Current understanding of FFA pathogenesis involves immune dysregulation.

Purpose of the Study:

  • To assess the impact of delgocitinib cream on the molecular signature of FFA lesions.
  • To evaluate the safety, tolerability, and preliminary efficacy of delgocitinib cream in FFA patients.

Main Methods:

  • A Phase 2a, randomized, double-blind, placebo-controlled trial.
  • 30 adult female patients with FFA were randomized to receive either 2% delgocitinib cream or vehicle cream.
  • Molecular biomarkers and transcriptomic profiles were analyzed after 12 weeks of treatment.

Main Results:

  • Delgocitinib cream significantly downregulated the T helper 1 biomarker CXCL9 expression in FFA lesions.
  • A significant improvement in the transcriptomic profile of delgocitinib-treated lesions was observed, while vehicle-treated lesions worsened.
  • Delgocitinib cream demonstrated good tolerability and positive trends in exploratory clinical efficacy endpoints.

Conclusions:

  • Delgocitinib cream altered the molecular signature of FFA lesions, suggesting a potential therapeutic mechanism.
  • Topical delgocitinib shows promise as a novel treatment for frontal fibrosing alopecia.
  • Further research with larger sample sizes is warranted to confirm efficacy.
Keywords:
FibrosisIFN-γPhase 2a trialScarring alopecia

More Related Videos

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.4K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Papillary Dermis01:11

Papillary Dermis

Dermis
The dermis might be considered the "core" of the integumentary system, as distinct from the epidermis and hypodermis. It contains blood and lymph vessels, nerves, and other structures, such as hair follicles and sweat glands. The dermis is made of two layers of connective tissue that comprise an interconnected mesh of elastin and collagenous fibers, produced by fibroblasts.
Papillary Layer
The papillary layer is made of loose, areolar connective tissue, which means the collagen...
5.4K
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K